- Condition: Arthritis, Rheumatoid
Interventions: Drug: JNJ-40346527; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Inflammatory Joint Diseases
Intervention:
Sponsors: Diakonhjemmet Hospital; Diakonhjemmet Hospital; University Hospital of North Norway; St. Olavs Hospital; Lillehammer Hospital for Rheumatic Diseases; Vestre Viken HF Drammen Hospital
Recruiting - verified April 2012 - Condition: Ankylosing Spondylitis
Interventions: Other: aerobic training; Other: Stretching exercises
Sponsors: Federal University of São Paulo; Federal University of São Paulo; Fundação de Amparo à Pesquisa do Estado de São Paulo
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis (RA)
Interventions: Drug: MK-8457 100 mg; Drug: MK-8457 100 mg; Drug: Dose-Matched Placebo; Drug: MK-8457 200 mg; Drug: MK-8457 25 mg; Drug: MK-8457
Sponsors: Merck; Merck
Not yet recruiting - verified April 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: ASP015K; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Not yet recruiting - verified May 2012 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0114-0006; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: MEDI5117; Biological: MEDI5117 Placebo
Sponsors: AstraZeneca; AstraZeneca
Not yet recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: UCB, Inc.; UCB, Inc.; ReSearch Pharmaceutical Services, Inc.
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550 or Placebo; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab; Drug: tocilizumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Arthritis; Rheumatoid
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo; Biological: Olokizumab 60 mg; Biological: Olokizumab 120 mg; Biological: Olokizumab 240 mg
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Certolizumab pegol
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2012 - Condition: Chronic Gouty Arthritis
Intervention: Biological: canakinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified November 2011 - Condition: Ankylosing Spondylitis
Intervention: Biological: Human umbilical cord-derived MSCs
Sponsors: Shandong University; Shandong University
Recruiting - verified April 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: BMS-817399; Drug: BMS-817399
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Polymyalgia Rheumatica (PMR)
Intervention: Drug: Tocilizumab
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; Genentech
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: BMS-945429 Placebo; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Drug: Methotrexate; Drug: Methotrexate; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo; Drug: Adalimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Prednisolone; Drug: dipyridamole; Drug: Prednisone; Drug: prednisolone-dipyridamole; Other: placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Gouty Arthritis
Interventions: Biological: Canakinumab, ACZ885; Drug: Triamcinolone acetonide
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Autoimmune Diseases; Systemic Inflammatory Process; Knee Pain Chronic; Osteoarthritis; Rheumatoid Arthritis
Interventions: Drug: Fish Oil; Drug: Vitamin D; Other: placebo pill
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: CDP6038
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Spondylitis, Ankylosing
Interventions: Biological: etanercept; Drug: Background NSAID; Other: PLACEBO; Drug: Background NSAID
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Spondyloarthritis; Ultrasonography
Intervention: Biological: Anti-TNF alpha therapy
Sponsors: Diakonhjemmet Hospital; Diakonhjemmet Hospital
Not yet recruiting - verified September 2010 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Rituximab; Drug: Placebo
Sponsors: Johann Wolfgang Goethe University Hospitals; Johann Wolfgang Goethe University Hospitals
Recruiting - verified June 2011 - Condition: Post Streptococcal Reactive Arthritis
Intervention: Device: echocardiogram
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Early Rheumatoid Arthritis
Interventions: Biological: adalimumab; Drug: methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Humira (adalimumab); Drug: Methotrexate (MTX)
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis
Intervention: Biological: HUMIRA (adalimumab)
Sponsors: Abbott; Abbott; Veeda Clinical Research, Brussels
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention: Other: This is a non-drug study. No treatment is mandated by the protocol. Routine blood draws (as per normal clinical care) will be taken through the study.
Sponsors: Abbott; Abbott; Clinical Trial End-Point (CTEP) Ltd; JSS Medical Research Inc.
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: adalimumab (Humira)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid ArthritisCondition: Rheumatoid Arthritis
Interventions: Drug: CAM3001; Drug: CAM3001; Drug: CAM3001; Drug: CAM3001
Sponsors: MedImmune LLC; MedImmune LLC; MedImmune Ltd
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: non-biological DMARDs
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified December 2011 - Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Endothelial Dysfunction; Inflammatory Disease Activity
Intervention:
Sponsors: Revmatismesykehuset AS; Revmatismesykehuset AS; Abbott
Recruiting - verified May 2009 - Condition: SPONDYLOARTHRITIS
Intervention: Drug: Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
Sponsors: Glostrup University Hospital, Copenhagen; Glostrup University Hospital, Copenhagen
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Lovastatin; Device: Lovastatin placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Autoimmunity Centers of Excellence
Recruiting - verified September 2011 - Condition: Spondylitis, Ankylosing
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012


